share_log

60 Degrees Pharmaceuticals | 10-K: FY2023 Annual Report

60 Degrees Pharmaceuticals | 10-K: FY2023 Annual Report

60 Degrees Pharmaceuticals | 10-K:2023财年年报
美股SEC公告 ·  04/01 14:37

Moomoo AI 已提取核心信息

60 Degrees Pharmaceuticals, a pharmaceutical company, has reported its annual financial performance and business developments. The company has decided not to recognize the benefits of U.S. Federal, state, and net deferred tax assets, leading to a full valuation allowance against its net deferred tax assets as of December 31, 2023, and December 31, 2022. The company did not establish reserves for uncertain tax positions as of the end of 2023 and 2022. Significant customers accounted for 92% of receivables and 93% of total net revenues as of December 31, 2023. The company's largest customer, the US government, ended its purchase support contract and clinical study in 2022, and no significant receivables or revenues from the government are anticipated in the near term. The company has exclusive relationships with distributors in...Show More
60 Degrees Pharmaceuticals, a pharmaceutical company, has reported its annual financial performance and business developments. The company has decided not to recognize the benefits of U.S. Federal, state, and net deferred tax assets, leading to a full valuation allowance against its net deferred tax assets as of December 31, 2023, and December 31, 2022. The company did not establish reserves for uncertain tax positions as of the end of 2023 and 2022. Significant customers accounted for 92% of receivables and 93% of total net revenues as of December 31, 2023. The company's largest customer, the US government, ended its purchase support contract and clinical study in 2022, and no significant receivables or revenues from the government are anticipated in the near term. The company has exclusive relationships with distributors in Australia and Europe, and any failure to perform by these distributors could disrupt patient access in those markets. The company's financial instruments are primarily cash, accounts receivable, inventory purchases, and borrowings, with a concentration of credit risk. Revenue is recognized in accordance with FASB ASC Topic No. 606, and the majority of revenues come from sales of its Arakoda™ product to resellers in the US and abroad. Research and development costs were recorded at $691,770 for the year ended December 31, 2023. The company's financial instruments are measured at fair value, with derivative liabilities carried at fair value based on Level 3 inputs. The company's future plans include managing its business in one identifiable segment and continuing to evaluate the impact of recently adopted and issued accounting pronouncements on its financial statement disclosures.
60 Degrees Pharmaceuticals,一家制药公司公布了其年度财务业绩和业务发展。该公司决定不承认美国联邦、州和净递延税资产的利益,导致其2023年12月31日和2022年12月31日的净递延税资产出现完全计价准备。该公司没有为2023年年末和2022年年末的不确定税项设立准备金。显著的客户占到了2023年12月31日应收账款的92%和总净收入的93%。该公司最大的客户美国政府在2022年结束了其采购支持合同和临床研究,未来没有来自政府的重大应收账款或收入。该公司在澳洲和欧洲拥有独家经销商关系,这些经销商的表现如果出现问题可能会影响这些市场上患者的使用。该公司的财务工具主要是现...展开全部
60 Degrees Pharmaceuticals,一家制药公司公布了其年度财务业绩和业务发展。该公司决定不承认美国联邦、州和净递延税资产的利益,导致其2023年12月31日和2022年12月31日的净递延税资产出现完全计价准备。该公司没有为2023年年末和2022年年末的不确定税项设立准备金。显著的客户占到了2023年12月31日应收账款的92%和总净收入的93%。该公司最大的客户美国政府在2022年结束了其采购支持合同和临床研究,未来没有来自政府的重大应收账款或收入。该公司在澳洲和欧洲拥有独家经销商关系,这些经销商的表现如果出现问题可能会影响这些市场上患者的使用。该公司的财务工具主要是现金、应收账款、存货采购和借款,信贷风险集中。按照FASB ASC 606准则确认营业收入,主要的收入来自于其Arakoda™产品在美国和国外的转售商销售。研发费用在2023年12月31日止年度记录为691,770美元。该公司的财务工具计量公允价值,衍生负债根据3级输入的公允价值进行计提。该公司未来的计划包括在一个可识别的业务领域中管理业务,并继续评估最近采用和发布的会计准则对其财务报表披露的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息